TransUnion has announced that its VantageScore 4.0 mortgage scores will be priced at $0.99 each until December 2028, providing stable and predictable costs for lenders. This pricing strategy follows the Federal Housing Finance Agency's decision to expand VantageScore 4.0 availability to Fannie Mae and Freddie Mac approved lenders, enhancing TransUnion's competitive position against FICO scores in the mortgage market. Lenders choosing FICO scores will also receive VantageScore 4.0 at no extra cost, further encouraging adoption. This move aims to increase lender confidence and market share for TransUnion's credit scoring product amid ongoing competition.
The TransUnion VantageScore 4.0 mortgage pricing update provides context for financial market participants. For readers following Financials, here is Pluang's market snapshot as of Oct 02, 2026 23:02 WIB: Among 85 priced US Financials-sector stocks, 40 rose and 43 fell. Notable movers include SCHW at USD 96.55 with a 1-day change of -1.85% and 100% buy order activity, RIOT at USD 19.96 with a 1-day change of +1.78% and 77% buy order activity, and ARCC at USD 18.82 with a 1-day change of -1.77% and 100% buy order activity.
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors in 24 patients with advanced primary cutaneous melanoma resistant to anti-PD-1 therapy. The treatment showed a 41.7% overall response...
NEAR Protocol announced a Q3 Backers Summit scheduled for October 28. The event will focus on discussions about its House of Stake issuance proposal, updates on NEAR AI, and integration plans. Tokenomics and AI are key topics, with special guests exp...
